Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax is safe and efficacious in relapsed/refractory AML.
Ganzel C, Ram R, Gural A, Wolach O, Gino-Moor S, Vainstein V, Nachmias B, Apel A, Koren-Michowitz M, Pasvolsky O, Yerushalmi R, Danylesko I, Cohen Y, Peretz G, Moshe Y, Zektser M, Yeganeh S, Rowe JM, Ofran Y. Ganzel C, et al. Among authors: vainstein v. Leuk Lymphoma. 2020 Sep;61(9):2221-2225. doi: 10.1080/10428194.2020.1761964. Epub 2020 May 18. Leuk Lymphoma. 2020. PMID: 32420775
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I, Perry C, Segman Y, Amit O, Bar-On Y, Katz OB, Gold R, Ribakovsky E, Avigdor A, Vainstein V, Goldschmidt N, Ringelstein-Harlev S, Horowitz NA, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Vezker M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Luttwak E, Herishanu Y, Ram R. Avivi I, et al. Among authors: vainstein v. Ann Hematol. 2022 Apr;101(4):755-762. doi: 10.1007/s00277-021-04749-9. Epub 2022 Jan 27. Ann Hematol. 2022. PMID: 35083525
Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis.
Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O. Shimony S, et al. Among authors: vainstein v. Ann Hematol. 2022 Sep;101(9):2011. doi: 10.1007/s00277-022-04929-1. Ann Hematol. 2022. PMID: 35869985 No abstract available.
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
Segman Y, Ribakovsky E, Avigdor A, Goldhecht Y, Vainstein V, Goldschmidt N, Harlev S, Horwitz N, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Zektser M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Herishanu Y, Ram R, Perry C, Avivi I. Segman Y, et al. Among authors: vainstein v. Leuk Lymphoma. 2021 Jan;62(1):118-124. doi: 10.1080/10428194.2020.1824069. Epub 2020 Sep 27. Leuk Lymphoma. 2021. PMID: 32981410
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
Lebel E, Goldschmidt N, Siegal T, Lossos A, Rosenberg S, Makranz C, Linetski E, Gatt ME, Gural A, Saban R, Lavie D, Vainstein V, Zimran E, Avni B, Grisaro S, Shaulov A, Nachmias B. Lebel E, et al. Among authors: vainstein v. Leuk Lymphoma. 2022 Sep;63(9):2102-2108. doi: 10.1080/10428194.2022.2064996. Epub 2022 May 2. Leuk Lymphoma. 2022. PMID: 35491706
48 results